Signature Resources Capital Management’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Signature Resources Capital Management’s Portfolio VRPX Stock Details VRPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2	Closed	-$35	–	403
2024 Q3	$35	Hold	2	–	–	﹤0.01%	378
2024 Q2	$26	Sell	2 -18	-90%	-$879	﹤0.01%	415
2024 Q1	$160	Buy	20 +18	+900%	+$1.58K	﹤0.01%	397
2023 Q4	$160	Buy	+2	New	+$300	﹤0.01%	398

Other funds holding VRPX

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

VWM

Vermillion Wealth Management Rosemount, Minnesota $427M AUM 12.63% 1-Year Est. Return

Signature Resources Capital Management's VRPX Position: Q4 2024 in Review

Signature Resources Capital Management sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q4 2024, closing a stake of 2 shares — an estimated $35 sold.

Signature Resources Capital Management first reported a position in VRPX in Q4 2023 and held it in 4 quarters. The position peaked at $160 in Q1 2024. 11 funds tracked by Wall St. Rank hold VRPX as of Q4 2024.

Signature Resources Capital Management reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Signature Resources Capital Management sold 2 Virpax Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $35.
Signature Resources Capital Management first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q4 2023 and held it in 4 quarters.
Signature Resources Capital Management's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $160 in Q1 2024.
11 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Signature Resources Capital Management's 13F filing for Q4 2024, filed 17 Jan 2025.